Abigail Klein Leichman
January 25, 2022

A fourth dose – second booster shot — of the Pfizer Covid-19 vaccine protects people over age 60 three times more against serious illness and about two times more against infection compared with three doses.

This is the conclusion of a preliminary data analysis performed by a team of researchers from Israel’s Ministry of Health, Weizmann Institute of Science, Technion-Israel Institute of Technology, Hebrew University, and Gartner Institute at Sheba Medical Center.

In early January, considering the rapid spread of the Omicron variant, a fourth dose of the vaccine was made available to Israelis aged 60 and over and to at-risk populations and healthcare workers. As of January 23, 592,510 Israelis have received the fourth dose.

The study looked at data from about 400,000 four-dose vaccinees and about 600,000 three-dose vaccinees, all over the age of 60.

The ministry said these preliminary results will be updated over time with additional follow-up data.

On January 18, ISRAEL21c reported that preliminary results of Sheba’s world-first study of the fourth dose indicate it is not effective enough against the current Omicron variant of the SARS-CoV-2 virus.

Dr. Gili Regev-Yochay, chief of Sheba’s Infectious Disease Unit, said that the second booster caused “a pretty nice increase in the number of antibodies – even a little higher than we had after the third dose – yet this is probably not enough for the Omicron.”

Regev-Yochay supports the Israeli government’s decision to offer a fourth vaccine to vulnerable populations since “it may give a little benefit. But probably not enough [benefit] to support a decision to give it to all of the population.”

Fighting for Israel's truth

We cover what makes life in Israel so special — it's people. A non-profit organization, ISRAEL21c's team of journalists are committed to telling stories that humanize Israelis and show their positive impact on our world. You can bring these stories to life by making a donation of $6/month. 

Jason Harris

Jason Harris

Executive Director

More on Health